Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation

1.

Silvestri, R., Nicolì, V., Gangadharannambiar, P., Crea, F., & Bootman, M. D. (2023). Calcium signalling pathways in prostate cancer initiation and progression. Nature Reviews Urology. https://doi.org/10.1038/s41585-023-00738-xCrossRefPubMed

2.

Rebello, R. J., Pearson, R. B., Hannan, R. D., & Furic, L. (2017). Therapeutic approaches targeting MYC-driven prostate cancer. Genes, 8, 71.CrossRefPubMedPubMedCentral

3.

Taichman, R. S., Loberg, R. D., Mehra, R., & Pienta, K. J. (2007). The evolving biology and treatment of prostate cancer. The Journal of clinical investigation, 117, 2351–2361. https://doi.org/10.1172/jci31791CrossRefPubMedPubMedCentral

4.

Crawford, E. D., Heidenreich, A., Lawrentschuk, N., Tombal, B., Pompeo, A. C. L., Mendoza-Valdes, A., Miller, K., Debruyne, F. M. J., & Klotz, L. (2019). Androgen-targeted therapy in men with prostate cancer: Evolving practice and future considerations. Prostate cancer and prostatic diseases, 22, 24–38. https://doi.org/10.1038/s41391-018-0079-0CrossRefPubMed

5.

Ehsani, M., David, F. O., Baniahmad, A. (2021). Androgen receptor-dependent mechanisms mediating drug resistance in prostate cancer. Cancers. 13. https://doi.org/10.3390/cancers13071534

6.

Hoang, D. T., Iczkowski, K. A., Kilari, D., See, W., & Nevalainen, M. T. (2017). Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget, 8, 3724–3745. https://doi.org/10.18632/oncotarget.12554CrossRefPubMed

7.

Merkens, L., Sailer, V., Lessel, D., Janzen, E., Greimeier, S., Kirfel, J., Perner, S., Pantel, K., Werner, S., & von Amsberg, G. (2022). Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. Journal of experimental & clinical cancer research : CR, 41, 46. https://doi.org/10.1186/s13046-022-02255-yCrossRefPubMedCentral

8.

Montironi, R., Cimadamore, A., Lopez-Beltran, A., Scarpelli, M., Aurilio, G., Santoni, M., Massari, F., Cheng, L. (2020). Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells 9. https://doi.org/10.3390/cells9051073

9.

Coleman, W. B. (2018). Chapter 25 — Molecular pathogenesis of prostate cancer. In Molecular pathology (Second Edition), Coleman, W.B., Tsongalis, G.J., Eds.; Academic Press. pp. 555–568.

10.

Avkshtol, V., Ruth, K. J., Ross, E. A., Hallman, M. A., Greenberg, R. E., Price, R. A., Jr., Leachman, B., Uzzo, R. G., Ma, C., Chen, D., et al. (2020). Ten-year update of a randomized, prospective trial of conventional fractionated versus moderate hypofractionated radiation therapy for localized prostate cancer. Journal of clinical oncology : Official journal of the American Society of Clinical Oncology, 38, 1676–1684. https://doi.org/10.1200/jco.19.01485CrossRefPubMed

11.

Hagiwara, M., Fushimi, A., Yamashita, N., Bhattacharya, A., Rajabi, H., Long, M. D., Yasumizu, Y., Oya, M., Liu, S., & Kufe, D. (2021). MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. Oncogene, 40, 4930–4940. https://doi.org/10.1038/s41388-021-01899-yCrossRefPubMedPubMedCentral

12.

Hagiwara, M., Fushimi, A., Bhattacharya, A., Yamashita, N., Morimoto, Y., Oya, M., Withers, H. G., Hu, Q., Liu, T., Liu, S., et al. (2022). MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Oncoimmunology, 11, 2029298. https://doi.org/10.1080/2162402x.2022.2029298CrossRefPubMedPubMedCentral

13.

Yang, Y., Liu, L., Li, M., Cheng, X., Fang, M., Zeng, Q., & Xu, Y. (2019). The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis. Biochimica et biophysica acta. Gene Regulatory Mechanisms, 1862, 834–845. https://doi.org/10.1016/j.bbagrm.2019.05.005CrossRefPubMed

14.

Zhao, D., Zhang, M., Huang, S., Liu, Q., Zhu, S., Li, Y., Jiang, W., Kiss, D. L., Cao, Q., Zhang, L., et al. (2022). CHD6 promotes broad nucleosome eviction for transcriptional activation in prostate cancer cells. Nucleic Acids Research, 50, 12186–12201. https://doi.org/10.1093/nar/gkac1090CrossRefPubMedPubMedCentral

15.

Ding, Y., Li, N., Dong, B., Guo, W., Wei, H., Chen, Q., Yuan, H., Han, Y., Chang, H., Kan, S., et al. (2019). Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. The Journal of clinical investigation, 129, 759–773. https://doi.org/10.1172/jci123557CrossRefPubMedPubMedCentral

16.

Rajwa, P., Quhal, F., Pradere, B., Gandaglia, G., Ploussard, G., Leapman, M. S., Gore, J. L., Paradysz, A., Tilki, D., Merseburger, A. S., et al. (2023). Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology, 20, 205–216. https://doi.org/10.1038/s41585-022-00680-4CrossRefPubMed

17.

Loeb, S., & Giri, V. N. (2021). Clinical implications of germline testing in newly diagnosed prostate cancer. European urology oncology, 4, 1–9. https://doi.org/10.1016/j.euo.2020.11.011CrossRefPubMed

18.

Oh, M., Alkhushaym, N., Fallatah, S., Althagafi, A., Aljadeed, R., Alsowaida, Y., Jeter, J., Martin, J. R., Babiker, H. M., McBride, A., et al. (2019). The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. The Prostate, 79, 880–895. https://doi.org/10.1002/pros.23795CrossRefPubMed

19.

Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016). Inherited DNA-repair gene mutations in men with metastatic prostate cancer. The New England Journal of Medicine, 375, 443–453. https://doi.org/10.1056/NEJMoa1603144CrossRefPubMedPubMedCentral

20.

Shore, N., Oliver, L., Shui, I., Gayle, A., Wong, O. Y., Kim, J., Payne, S., Amin, S., & Ghate, S. (2021). Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations. The Journal of urology, 205, 977–986. https://doi.org/10.1097/ju.0000000000001570CrossRefPubMed

21.

Wang, Z., Wang, T., Hong, D., Dong, B., Wang, Y., Huang, H., Zhang, W., Lian, B., Ji, B., Shi, H., et al. (2022). Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer. iScience, 25, 104576. https://doi.org/10.1016/j.isci.2022.104576CrossRefPubMedPubMedCentral

22.

Lv, S., Wu, Z., Luo, M., Zhang, Y., Zhang, J., Pascal, L. E., Wang, Z., & Wei, Q. (2022). Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer. Cell Death & Disease, 13, 754. https://doi.org/10.1038/s41419-022-05182-0CrossRef

23.

Tang, D. G. (2022). Understanding and targeting prostate cancer cell heterogeneity and plasticity. Seminars in Cancer Biology, 82, 68–93. https://doi.org/10.1016/j.semcancer.2021.11.001CrossRefPubMed

24.

Cyrta, J., Prandi, D., Arora, A., Hovelson, D. H., Sboner, A., Rodriguez, A., Fedrizzi, T., Beltran, H., Robinson, D. R., Gopalan, A., et al. (2022). Comparative genomics of primary prostate cancer and paired metastases: Insights from 12 molecular case studies. The Journal of pathology, 257, 274–284. https://doi.org/10.1002/path.5887CrossRefPubMed

25.

Sun, G., Ma, S., Zheng, Z., Wang, X., Chen, S., Chang, T., Liang, Z., Jiang, Y., Xu, S., & Liu, R. (2022). Multi-omics analysis of expression and prognostic value of NSUN members in prostate cancer. Frontiers in Oncology, 12, 965571. https://doi.org/10.3389/fonc.2022.965571CrossRefPubMedPubMedCentral

26.

Jia, D., Zhou, Z., Kwon, O. J., Zhang, L., Wei, X., Zhang, Y., Yi, M., Roudier, M. P., Regier, M. C., Dumpit, R., et al. (2022). Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity. Nature Communications, 13, 6828. https://doi.org/10.1038/s41467-022-34665-zCrossRefPubMedPubMedCentral

27.

Chang, M., He, Y., Liu, C., Lin, R., Huang, X., Liang, D., Zhang, J., & Lu, Y. (2022). Downregulation of SEPTIN5 inhibits prostate cancer progression by increasing CD8(+) T cell infiltration. International Journal of Biological Sciences, 18, 6035–6051. https://doi.org/10.7150/ijbs.76573CrossRefPubMedPubMedCentral

28.

Ding, L., Wang, R., Zheng, Q., Shen, D., Wang, H., Lu, Z., Luo, W., Xie, H., Ren, L., Jiang, M., et al. (2022). circPDE5A regulates prostate cancer metastasis via controlling WTAP-dependent N6-methyladenisine methylation of EIF3C mRNA. Journal of Experimental & Clinical Cancer Research : CR, 41, 187. https://doi.org/10.1186/s13046-022-02391-5CrossRefPubMedCentral

29.

Li, Z., Li, B., Yu, H., Wang, P., Wang, W., Hou, P., Li, M., Chu, S., Zheng, J., Mao, L., et al. (2022). DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability. Oncogene, 41, 3991–4002. https://doi.org/10.1038/s41388-022-02404-9CrossRefPubMed

30.

Vasan, N., Baselga, J., & Hyman, D. M. (2019). A view on drug resistance in cancer. Nature, 575, 299–309. https://doi.org/10.1038/s41586-019-1730-1CrossRefPubMedPubMedCentral

31.

Goldie, J. H., & Coldman, A. J. (1984). The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Research, 44, 3643–3653.PubMed

32.

Fisher, B., Slack, N. H., & Bross, I. D. (1969). Cancer of the breast: Size of neoplasm and prognosis. Cancer, 24, 1071–1080. https://doi.org/10.1002/1097-0142(196911)24:5%3c1071::aid-cncr2820240533%3e3.0.co;2-hCrossRefPubMed

33.

Skipper, H. E., Schabel, F. M., Jr., & Wilcox, W. S. (1964). Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemotherapy Reports, 35, 1–111.PubMed

34.

Goldie, J. H., & Coldman, A. J. (1979). A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Reports, 63, 1727–1733.PubMed

35.

Luria, S. E., & Delbrück, M. (1943). Mutations of bacteria from virus sensitivity to virus resistance. Genetics, 28, 491–511. https://doi.org/10.1093/genetics/28.6.491CrossRefPubMedPubMedCentral

36.

Tannock, I. F. (2015). Cancer: Resistance through repopulation. Nature, 517, 152–153. https://doi.org/10.1038/nature14075CrossRefPubMed

37.

Nowell, P. C. (1976). The clonal evolution of tumor cell populations. Science (New York, N.Y.), 194, 23–28. https://doi.org/10.1126/science.959840CrossRefPubMed

38.

Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Børresen-Dale, A. L., et al. (2013). Signatures of mutational processes in human cancer. Nature, 500, 415–421. https://doi.org/10.1038/nature12477CrossRefPubMedPubMedCentral

39.

Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998). Genetic instabilities in human cancers. Nature, 396, 643–649. https://doi.org/10.1038/25292CrossRefPubMed

40.

Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011). Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell, 144, 27–40. https://doi.org/10.1016/j.cell.2010.11.055CrossRefPubMedPubMedCentral

41.

Sansregret, L., Vanhaesebroeck, B., & Swanton, C. (2018). Determinants and clinical implications of chromosomal instability in cancer. Nature Reviews. Clinical Oncology, 15, 139–150. https://doi.org/10.1038/nrclinonc.2017.198CrossRefPubMed

42.

Jain, R. K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (New York, N.Y.), 307, 58–62. https://doi.org/10.1126/science.1104819CrossRefPubMed

43.

Minchinton, A. I., & Tannock, I. F. (2006). Drug penetration in solid tumours. Nature Reviews. Cancer, 6, 583–592. https://doi.org/10.1038/nrc1893CrossRefPubMed

44.

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019). Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology, 20, 711–718. https://doi.org/10.1016/s1470-2045(19)30020-8CrossRefPubMed

45.

Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019). Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. The New England Journal of Medicine, 380, 1116–1127. https://doi.org/10.1056/NEJMoa1816714CrossRefPubMed

46.

Liu, H. J., & Xu, P. (2022). Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor. Advanced Drug Delivery Reviews, 191, 114619. https://doi.org/10.1016/j.addr.2022.114619CrossRefPubMedPubMedCentral

47.

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13, 714–726. https://doi.org/10.1038/nrc3599CrossRefPubMed

48.

Mirzaei, S., Gholami, M. H., Hashemi, F., Zabolian, A., Farahani, M. V., Hushmandi, K., Zarrabi, A., Goldman, A., Ashrafizadeh, M., & Orive, G. (2022). Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discovery Today, 27, 436–455. https://doi.org/10.1016/j.drudis.2021.09.020CrossRefPubMed

49.

Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: Role of ATP–dependent transporters. Nature Reviews Cancer, 2, 48–58.CrossRefPubMed

50.

Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Review of Pharmacology and Toxicology, 39, 361–398.CrossRefPubMed

51.

Choi, C.-H. (2005). ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell International, 5, 1–13.CrossRef

52.

Thomas, H., & Coley, H. M. (2003). Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control, 10, 159–165.CrossRefPubMed

53.

Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., & Fleming, D. R. (2005). Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer, 104, 682–691.CrossRefPubMed

54.

Meijer, C., Mulder, N. H., Timmer-Bosscha, H., Sluiter, W. J., Meersma, G. J., & de Vries, E. G. (1992). Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Research, 52, 6885–6889.PubMed

55.

Schwartz, P. M., Moir, R. D., Hyde, C. M., Turek, P. J., & Handschumacher, R. E. (1985). Role of uridine phosphorylase in the anabolism of 5-fluorouracil. Biochemical Pharmacology, 34, 3585–3589.CrossRefPubMed

56.

Houghton, J. A., & Houghton, P. J. (1983). Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. European Journal of Cancer and Clinical Oncology, 19, 807–815.CrossRefPubMed

57.

Malet-Martino, M., & Martino, R. (2002). Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. The Oncologist, 7, 288–323.CrossRefPubMed

58.

Kosuri, K., Wu, X., Wang, L., Villalona-Calero, M., & Otterson, G. (2010). An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochemical and Biophysical Research Communications, 391, 1465–1470.CrossRefPubMed

59.

Bélanger, A.-S., Tojcic, J., Harvey, M., & Guillemette, C. (2010). Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Molecular Biology, 11, 1–11.CrossRef

60.

Toffoli, G., Cecchin, E., Gasparini, G., D’Andrea, M., Azzarello, G., Basso, U., Mini, E., Pessa, S., De Mattia, E., & Lo Re, G. (2010). Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28, 866–871.CrossRefPubMed

61.

Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2020). Challenges and opportunities in cancer drug resistance. Chemical Reviews, 121, 3297–3351.CrossRefPubMed

62.

Joyce, H., McCann, A., Clynes, M., & Larkin, A. (2015). Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opinion on Drug Metabolism & Toxicology, 11, 795–809.CrossRef

63.

Wood, K. C. (2015). Mapping the pathways of resistance to targeted therapies. Cancer Research, 75, 4247–4251.CrossRefPubMedPubMedCentral

64.

Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., & Wyczalkowski, M. A. (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502, 333–339.CrossRefPubMedPubMedCentral

65.

Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell, 137, 835–848.CrossRefPubMedPubMedCentral

66.

Zhang, T., Brazhnik, P., & Tyson, J. J. (2009). Computational analysis of dynamical responses to the intrinsic pathway of programmed cell death. Biophysical Journal, 97, 415–434.CrossRefPubMedPubMedCentral

67.

Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., & Kohn, K. W. (2004). Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene, 23, 2934–2949.CrossRefPubMed

68.

Zhivotovsky, B., & Orrenius, S. (2003). Defects in the apoptotic machinery of cancer cells: Role in drug resistance. In: Proceedings of the Seminars in cancer biology, pp. 125–134.

69.

Indran, I. R., Tufo, G., Pervaiz, S., & Brenner, C. (2011). Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochimica et Biophysica Acta (BBA)-Bioenergetics, 1807, 735–745.CrossRefPubMed

70.

Liang, X., Zhang, H., Wang, Z., Zhang, X., Dai, Z., Zhang, J., Luo, P., Zhang, L., Hu, J., Liu, Z., et al. (2022). JMJD8 Is an M2 macrophage biomarker, and it associates with DNA damage repair to facilitate stemness maintenance, chemoresistance, and immunosuppression in pan-cancer. Frontiers in immunology, 13, 875786. https://doi.org/10.3389/fimmu.2022.875786CrossRefPubMedPubMedCentral

71.

Zhou, W., Xu, Y., Zhang, J., Zhang, P., Yao, Z., Yan, Z., Wang, H., Chu, J., Yao, S., Zhao, S., et al. (2022). MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma. Leukemia, 36, 1861–1869. https://doi.org/10.1038/s41375-022-01565-6CrossRefPubMedPubMedCentral

72.

Su, Y., Wu, C., Chang, Y., Li, L., Chen, Y., Jia, X., Wang, X., Lv, Y., Yu, B., & Yuan, J. (2022). USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells. Breast Cancer Research and Treatment, 196, 31–44. https://doi.org/10.1007/s10549-022-06711-3CrossRefPubMed

73.

Tang, C., Qiu, S., Mou, W., Xu, J., & Wang, P. (2022). Excessive activation of HOXB13/PIMREG axis promotes hepatocellular carcinoma progression and drug resistance. Biochemical and Biophysical Research Communications, 623, 81–88. https://doi.org/10.1016/j.bbrc.2022.07.066CrossRefPubMed

74.

Nicholson, H. A., Sawers, L., Clarke, R. G., Hiom, K. J., Ferguson, M. J., & Smith, G. (2022). Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer. British Journal of Cancer, 127, 1340–1351. https://doi.org/10.1038/s41416-022-01899-zCrossRefPubMedPubMedCentral

75.

Zhang, C., Chen, L., Sun, L., Jin, H., Ren, K., Liu, S., Qian, Y., Li, S., Li, F., Zhu, C., et al. (2023). BMAL1 collaborates with CLOCK to directly promote DNA double-strand break repair and tumor chemoresistance. Oncogene, 42, 967–979. https://doi.org/10.1038/s41388-023-02603-yCrossRefPubMedPubMedCentral

76.

Jin, J., Ma, M., Shi, S., Wang, J., Xiao, P., Yu, H. F., Zhang, C., Guo, Q., Yu, Z., Lou, Z., et al. (2022). Copper enhances genotoxic drug resistance via ATOX1 activated DNA damage repair. Cancer Letters, 536, 215651. https://doi.org/10.1016/j.canlet.2022.215651CrossRefPubMed

77.

Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020). Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy, 5, 8. https://doi.org/10.1038/s41392-020-0110-5CrossRefPubMedPubMedCentral

78.

Chen, W., Dong, J., Haiech, J., Kilhoffer, M. C., & Zeniou, M. (2016). Cancer stem cell quiescence and plasticity as major challenges in cancer therapy. Stem Cells International, 2016, 1740936. https://doi.org/10.1155/2016/1740936CrossRefPubMedPubMedCentral

79.

Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645–648. https://doi.org/10.1038/367645a0CrossRefPubMed

80.

Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730–737. https://doi.org/10.1038/nm0797-730CrossRefPubMed

81.

Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., Fujii, M., Date, S., Sugimoto, S., Kanai, T., & Sato, T. (2017). Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature, 545, 187–192. https://doi.org/10.1038/nature22081CrossRefPubMed

82.

Shibata, M., Hoque, M. O. (2019). Targeting cancer stem cells: A strategy for effective eradication of cancer. Cancers, 11. https://doi.org/10.3390/cancers11050732

83.

Visvader, J. E., & Lindeman, G. J. (2012). Cancer stem cells: Current status and evolving complexities. Cell Stem Cell, 10, 717–728. https://doi.org/10.1016/j.stem.2012.05.007CrossRefPubMed

84.

Ajani, J. A., Song, S., Hochster, H. S., & Steinberg, I. B. (2015). Cancer stem cells: The promise and the potential. Seminars in Oncology, 42(Suppl 1), S3-17. https://doi.org/10.1053/j.seminoncol.2015.01.001CrossRefPubMed

85.

Chen, P. M., Wong, C. N., Wong, C. N., Chu, P. Y. (2023). Actin-like protein 6A expression correlates with cancer stem cell-like features and poor prognosis in ovarian cancer. International Journal of Molecular Sciences, 24. https://doi.org/10.3390/ijms24032016

86.

Sun, K., Shen, H., He, S., & Liu, Y. (2022). MASM inhibits cancer stem cell-like characteristics of EpCAM(+) cells via AKT/GSK3β/β-catenin signaling. American Journal of Translational Research, 14, 8380–8389.PubMedPubMedCentral

87.

Chen, Y., Yang, Z., He, X., Zhu, W., Wang, Y., Li, J., Han, Z., Wen, J., Liu, W., Yang, Y., et al. (2023). Proanthocyanidins inhibited colorectal cancer stem cell characteristics through Wnt/β-catenin signaling. Environmental Toxicology. https://doi.org/10.1002/tox.23924CrossRefPubMed

88.

Gonzalez-Callejo, P., Guo, Z., Ziglari, T., Claudio, N. M., Nguyen, K. H., Oshimori, N., Seras-Franzoso, J., & Pucci, F. (2023). Cancer stem cell-derived extracellular vesicles preferentially target MHC-II-macrophages and PD1+ T cells in the tumor microenvironment. PLoS ONE, 18, e0279400. https://doi.org/10.1371/journal.pone.0279400CrossRefPubMedPubMedCentral

89.

Liao, W., Zhang, L., Chen, X., Xiang, J., Zheng, Q., Chen, N., Zhao, M., Zhang, G., Xiao, X., Zhou, G., et al. (2023). Targeting cancer stem cells and signalling pathways through phytochemicals: A promising approach against colorectal cancer. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 108, 154524. https://doi.org/10.1016/j.phymed.2022.154524CrossRefPubMed

90.

Ashrafizadeh, M., Zhang, W., Zou, R., Sethi, G., Klionsky, D. J., & Zhang, X. (2023). A bioinformatics analysis, pre-clinical and clinical conception of autophagy in pancreatic cancer: Complexity and simplicity in crosstalk. Pharmacological Research, 194, 106822. https://doi.org/10.1016/j.phrs.2023.106822CrossRefPubMed

91.

Qin, Y., Ashrafizadeh, M., Mongiardini, V., Grimaldi, B., Crea, F., Rietdorf, K., Győrffy, B., Klionsky, D. J., Ren, J., Zhang, W., et al. (2023). Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence. Cancer Letters, 570, 216307. https://doi.org/10.1016/j.canlet.2023.216307CrossRefPubMed

92.

Zhang, S., Liu, X., Abdulmomen Ali Mohammed, S., Li, H., Cai, W., Guan, W., Liu, D., Wei, Y., Rong, D., Fang, Y., et al. (2022). Adaptor SH3BGRL drives autophagy-mediated chemoresistance through promoting PIK3C3 translation and ATG12 stability in breast cancers. Autophagy, 18, 1822–1840. https://doi.org/10.1080/15548627.2021.2002108CrossRefPubMed

93.

Luo, M., Deng, X., Chen, Z., & Hu, Y. (2023). Circular RNA circPOFUT1 enhances malignant phenotypes and autophagy-associated chemoresistance via sequestrating miR-488-3p to activate the PLAG1-ATG12 axis in gastric cancer. Cell Death & Disease, 14, 10. https://doi.org/10.1038/s41419-022-05506-0CrossRef

94.

Zhang, S. R., Li, J., Chen, J. X., Chen, G., Chen, J. Y., Fu, H. W., & Zhou, B. (2022). SMC4 enhances the chemoresistance of hepatoma cells by promoting autophagy. Annals of Translational Medicine, 10, 1308. https://doi.org/10.21037/atm-22-3623CrossRefPubMedPubMedCentral

95.

Sun, Y., Shen, W., Hu, S., Lyu, Q., Wang, Q., Wei, T., Zhu, W., & Zhang, J. (2023). METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. Journal of Experimental & Clinical Cancer Research : CR, 42, 65. https://doi.org/10.1186/s13046-023-02638-9CrossRefPubMedCentral

96.

Shen, Z., Zhou, L., Zhang, C., & Xu, J. (2020). Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel. Cancer Letters, 468, 88–101. https://doi.org/10.1016/j.canlet.2019.10.006CrossRefPubMed

97.

Zhou, Q., Chen, X., He, H., Peng, S., Zhang, Y., Zhang, J., Cheng, L., Liu, S., Huang, M., Xie, R., et al. (2021). WD repeat domain 5 promotes chemoresistance and programmed death-ligand 1 expression in prostate cancer. Theranostics, 11, 4809–4824. https://doi.org/10.7150/thno.55814CrossRefPubMedPubMedCentral

98.

Bai, L., Li, X., Yang, Y., Zhao, R., White, E. Z., Danaher, A., Bowen, N. J., Hinton, C. V., Cook, N., Li, D., et al. (2023). Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models. Translational Oncology, 34, 101707. https://doi.org/10.1016/j.tranon.2023.101707CrossRefPubMedPubMedCentral

99.

Xie, C., Wang, Z., Ba, Y., Aguilar, J., Kyan, A., Zhong, L., & Hao, J. (2023). BMP signaling inhibition overcomes chemoresistance of prostate cancer. American Journal of Cancer Research, 13, 4073–4086.PubMedPubMedCentral

100.

Ma, B., Shao, H., Jiang, X., Wang, Z., Wu, C. C., Whaley, D., & Wells, A. (2021). Akt isoforms differentially provide for chemoresistance in prostate cancer. Cancer Biology & Medicine, 19, 635–650. https://doi.org/10.20892/j.issn.2095-3941.2020.0747CrossRef

101.

Orellana-Serradell, O., Herrera, D., Castellón, E. A., & Contreras, H. R. (2019). The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines. Asian Journal of Andrology, 21, 460–467. https://doi.org/10.4103/aja.aja_1_19CrossRefPubMedPubMedCentral

102.

Wang, W., Wang, L., Mizokami, A., Shi, J., Zou, C., Dai, J., Keller, E. T., Lu, Y., & Zhang, J. (2017). Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer, 36, 35. https://doi.org/10.1186/s40880-017-0203-xCrossRefPubMedPubMedCentral

103.

Li, X., Gera, L., Zhang, S., Chen, Y., Lou, L., Wilson, L. M., Xie, Z. R., Sautto, G., Liu, D., Danaher, A., et al. (2021). Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics, 11, 6873–6890. https://doi.org/10.7150/thno.49235CrossRefPubMedPubMedCentral

104.

Luo, S., Shao, L., Chen, Z., Hu, D., Jiang, L., & Tang, W. (2020). NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway. Experimental Cell Research, 390, 111981. https://doi.org/10.1016/j.yexcr.2020.111981CrossRefPubMed

105.

Liu, C., Li, Z., Bi, L., Li, K., Zhou, B., Xu, C., Huang, J., & Xu, K. (2014). NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells. Molecular and Cellular Biochemistry, 393, 265–270. https://doi.org/10.1007/s11010-014-2069-4CrossRefPubMed

106.

Biernacka, K. M., Uzoh, C. C., Zeng, L., Persad, R. A., Bahl, A., Gillatt, D., Perks, C. M., & Holly, J. M. (2013). Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocrine-Related Cancer, 20, 741–751. https://doi.org/10.1530/erc-13-0077CrossRefPubMed

107.

Kato, T., Fujita, Y., Nakane, K., Kojima, T., Nozawa, Y., Deguchi, T., & Ito, M. (2012). ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression. Biochemical and Biophysical Research Communications, 417, 966–971. https://doi.org/10.1016/j.bbrc.2011.12.047CrossRefPubMed

108.

Stafford, M. Y. C., McKenna, D. J. (2023). MiR-182 is upregulated in prostate cancer and contributes to tumor progression by targeting MITF. International Journal of Molecular Sciences, 24. https://doi.org/10.3390/ijms24031824

109.

Bozgeyik, E., Arslan, A., Temiz, E., Batar, B., Koyuncu, I., & Tozkir, H. (2022). miR-320a promotes p53-dependent apoptosis of prostate cancer cells by negatively regulating TP73-AS1 invitro. Biochemical and Biophysical Research Communications, 619, 130–136. https://doi.org/10.1016/j.bbrc.2022.06.034CrossRefPubMed

110.

Wang, C., Li, W., Hu, Q., Feng, N., Liu, C., Shi, N., Chen, S., Chen, M., Guan, H., You, Z., et al. (2022). Transgenic construction and functional miRNA analysis identify the role of miR-7 in prostate cancer suppression. Oncogene, 41, 4645–4657. https://doi.org/10.1038/s41388-022-02461-0CrossRefPubMed

111.

Wang, Y., Lieberman, R., Pan, J., Zhang, Q., Du, M., Zhang, P., Nevalainen, M., Kohli, M., Shenoy, N. K., Meng, H., et al. (2016). miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Molecular Cancer, 15, 70. https://doi.org/10.1186/s12943-016-0556-9CrossRefPubMedPubMedCentral

112.

Fujita, Y., Kojima, K., Hamada, N., Ohhashi, R., Akao, Y., Nozawa, Y., Deguchi, T., & Ito, M. (2008). Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochemical and Biophysical Research Communications, 377, 114–119. https://doi.org/10.1016/j.bbrc.2008.09.086CrossRefPubMed

113.

Gujrati, H., Ha, S., Waseem, M., Wang, B. D. (2022). Downregulation of miR-99b-5p and upregulation of nuclear mTOR cooperatively promotes the tumor aggressiveness and drug resistance in African American prostate cancer. International Journal of Molecular Sciences, 23. https://doi.org/10.3390/ijms23179643

114.

Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., Sabet, S., Khoshbakht, M. A., Hashemi, M., Hushmandi, K., et al. (2022). Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. Journal of Hematology & Oncology, 15, 83. https://doi.org/10.1186/s13045-022-01305-4CrossRef

115.

Cao, Z., Xu, L., & Zhao, S. (2019). Exosome-derived miR-27a produced by PSC-27 cells contributes to prostate cancer chemoresistance through p53. Biochemical and Biophysical Research Communications, 515, 345–351. https://doi.org/10.1016/j.bbrc.2019.05.120CrossRefPubMed

116.

Shi, G. H., Ye, D. W., Yao, X. D., Zhang, S. L., Dai, B., Zhang, H. L., Shen, Y. J., Zhu, Y., Zhu, Y. P., Xiao, W. J., et al. (2010). Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacologica Sinica, 31, 867–873. https://doi.org/10.1038/aps.2010.48CrossRefPubMedPubMedCentral

117.

Zhu, J., Qin, P., Cao, C., Dai, G., Xu, L., & Yang, D. (2021). Use of miR-145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer. Oncology Reports, 45, 963–974. https://doi.org/10.3892/or.2021.7925CrossRefPubMedPubMedCentral

118.

Zhou, P., Ma, L., Zhou, J., Jiang, M., Rao, E., Zhao, Y., & Guo, F. (2016). miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells. International Journal of Oncology, 48, 1737–1748. https://doi.org/10.3892/ijo.2016.3392CrossRefPubMed

119.

Zhong, J., Huang, R., Su, Z., Zhang, M., Xu, M., Gong, J., Chen, N., Zeng, H., Chen, X., & Zhou, Q. (2017). Downregulation of miR-199a-5p promotes prostate adeno-carcinoma progression through loss of its inhibition of HIF-1α. Oncotarget, 8, 83523–83538. https://doi.org/10.18632/oncotarget.18315CrossRefPubMedPubMedCentral

120.

Tseng, J. C., Huang, S. H., Lin, C. Y., Wang, B. J., Huang, S. F., Shen, Y. Y., & Chuu, C. P. (2020). ROR2 suppresses metastasis of prostate cancer via regulation of miR-199a-5p-PIAS3-AKT2 signaling axis. Cell Death & Disease, 11, 376. https://doi.org/10.1038/s41419-020-2587-9CrossRef

121.

Chen, L., Cao, H., & Feng, Y. (2018). MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. World Journal of Urology, 36, 357–365. https://doi.org/10.1007/s00345-017-2143-0CrossRefPubMed

122.

Xu, X., Wang, Y., Deng, H., Liu, C., Wu, J., & Lai, M. (2018). HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway. Oncotarget, 9, 9963–9974. https://doi.org/10.18632/oncotarget.24133CrossRefPubMedPubMedCentral

123.

Wu, C., Miao, C., Tang, Q., Zhou, X., Xi, P., Chang, P., Hua, L., & Ni, H. (2020). MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression. Journal of Cellular and Molecular Medicine, 24, 2098–2108. https://doi.org/10.1111/jcmm.14050CrossRefPubMed

124.

Yang, Z., Chen, J. S., Wen, J. K., Gao, H. T., Zheng, B., Qu, C. B., Liu, K. L., Zhang, M. L., Gu, J. F., Li, J. D., et al. (2017). Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel. Journal of Experimental & Clinical Cancer Research : CR, 36, 178. https://doi.org/10.1186/s13046-017-0649-3CrossRefPubMedCentral

125.

Mirzaei, S., Paskeh, M. D. A., Okina, E., Gholami, M. H., Hushmandi, K., Hashemi, M., Kalu, A., Zarrabi, A., Nabavi, N., Rabiee, N., et al. (2022). Molecular landscape of LncRNAs in prostate cancer: A focus on pathways and therapeutic targets for intervention. Journal of Experimental & Clinical Cancer Research : CR, 41, 214. https://doi.org/10.1186/s13046-022-02406-1CrossRefPubMedCentral

126.

Liu, B., Li, X., Wang, D., Yu, Y., Lu, D., Chen, L., Lv, F., Li, Y., Cheng, L., Song, Y., et al. (2022). CEMIP promotes extracellular matrix-detached prostate cancer cell survival by inhibiting ferroptosis. Cancer Science, 113, 2056–2070. https://doi.org/10.1111/cas.15356CrossRefPubMedPubMedCentral

127.

Cheng, L., He, Q., Liu, B., Chen, L., Lv, F., Li, X., Li, Y., Liu, C., Song, Y., & Xing, Y. (2023). SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4. Cell Death & Disease, 14, 74. https://doi.org/10.1038/s41419-023-05614-5CrossRef

128.

Jiang, X., Guo, S., Xu, M., Ma, B., Liu, R., Xu, Y., & Zhang, Y. (2022). TFAP2C-mediated lncRNA PCAT1 inhibits ferroptosis in docetaxel-resistant prostate cancer through c-Myc/miR-25-3p/SLC7A11 signaling. Frontiers in Oncology, 12, 862015. https://doi.org/10.3389/fonc.2022.862015CrossRefPubMedPubMedCentral

129.

Jiang, H., Xiong, W., Chen, L., Lv, Z., Yang, C., & Li, Y. (2019). Knockdown of the long noncoding RNA HOTTIP inhibits cell proliferation and enhances cell sensitivity to cisplatin by suppressing the Wnt/β-catenin pathway in prostate cancer. Journal of Cellular Biochemistry, 120, 8965–8974. https://doi.org/10.1002/jcb.27851CrossRefPubMed

130.

Cao, C., Sun, G., & Liu, C. (2020). Long non-coding RNA SNHG6 regulates the sensitivity of prostate cancer cells to paclitaxel by sponging miR-186. Cancer Cell International, 20, 381. https://doi.org/10.1186/s12935-020-01462-xCrossRefPubMedPubMedCentral

131.

Xing, Z., Li, S., Xing, J., Yu, G., Wang, G., & Liu, Z. (2022). Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p/TrkB axis. Laboratory Investigation; A Journal of Technical Methods and Pathology, 102, 602–612. https://doi.org/10.1038/s41374-022-00736-4CrossRefPubMedPubMedCentral

132.

Gao, W., Lin, S., Cheng, C., Zhu, A., Hu, Y., Shi, Z., Zhang, X., & Hong, Z. (2019). Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells to docetaxel. Archives of Biochemistry and Biophysics, 665, 69–78. https://doi.org/10.1016/j.abb.2018.01.013CrossRefPubMed

133.

Li, X., Han, X., Wei, P., Yang, J., & Sun, J. (2020). Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1. Cancer Biology & Therapy, 21, 452–462. https://doi.org/10.1080/15384047.2020.1727700CrossRef

134.

Wang, C., Ding, T., Yang, D., Zhang, P., Hu, X., Qin, W., & Zheng, J. (2021). The lncRNA OGFRP1/miR-149-5p/IL-6 axis regulates prostate cancer chemoresistance. Pathology, Research and Practice, 224, 153535. https://doi.org/10.1016/j.prp.2021.153535CrossRefPubMed

135.

Shi, T., Li, R., Duan, P., Guan, Y., Zhang, D., Ding, Z., & Ruan, X. (2022). TRPM2-AS promotes paclitaxel resistance in prostate cancer by regulating FOXK1 via sponging miR-497-5p. Drug Development Research, 83, 967–978. https://doi.org/10.1002/ddr.21924CrossRefPubMed

136.

Wang, Y. Y., & Chen, C. (2022). lncRNA-DANCR promotes Taxol resistance of prostate cancer cells through modulating the miR-33b-5p-LDHA axis. Disease Markers, 2022, 9516774. https://doi.org/10.1155/2022/9516774CrossRefPubMedPubMedCentral

137.

Gu, P., Chen, X., Xie, R., Han, J., Xie, W., Wang, B., Dong, W., Chen, C., Yang, M., Jiang, J., et al. (2017). lncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5. Molecular therapy : The Journal of the American Society of Gene Therapy, 25, 1959–1973. https://doi.org/10.1016/j.ymthe.2017.04.016CrossRefPubMed

138.

Ding, X., Sun, J., & Zhang, X. (2022). Circ_0076305 facilitates prostate cancer development via sponging miR-411-5p and regulating PGK1. Andrologia, 54, e14406. https://doi.org/10.1111/and.14406CrossRefPubMed

139.

Zhang, G., Liu, Y., Yang, J., Wang, H., & Xing, Z. (2022). Inhibition of circ_0081234 reduces prostate cancer tumor growth and metastasis via the miR-1/MAP 3 K1 axis. The Journal of Gene Medicine, 24, e3376. https://doi.org/10.1002/jgm.3376CrossRefPubMed

140.

Cai, F., Li, J., Zhang, J., & Huang, S. (2022). Knockdown of Circ_CCNB2 sensitizes prostate cancer to radiation through repressing autophagy by the miR-30b-5p/KIF18A axis. Cancer Biotherapy & Radiopharmaceuticals, 37, 480–493. https://doi.org/10.1089/cbr.2019.3538CrossRef

141.

Yu, T., Du, H., & Sun, C. (2023). Circ-ABCC4 contributes to prostate cancer progression and radioresistance by mediating miR-1253/SOX4 cascade. Anti-Cancer Drugs, 34, 155–165. https://doi.org/10.1097/cad.0000000000001361CrossRefPubMed

142.

Zhang, Y., Liu, F., Feng, Y., Xu, X., Wang, Y., Zhu, S., Dong, J., Zhao, S., Xu, B., & Feng, N. (2022). CircRNA circ_0006156 inhibits the metastasis of prostate cancer by blocking the ubiquitination of S100A9. Cancer Gene Therapy, 29, 1731–1741. https://doi.org/10.1038/s41417-022-00492-zCrossRefPubMedPubMedCentral

143.

Chen, L., Song, Y., Hou, T., Li, X., Cheng, L., Li, Y., & Xing, Y. (2022). Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism. Journal of Experimental & Clinical Cancer Research : CR, 41, 194. https://doi.org/10.1186/s13046-022-02404-3CrossRefPubMedCentral

144.

Gao, Y., Liu, J., Huan, J., & Che, F. (2020). Downregulation of circular RNA hsa_circ_0000735 boosts prostate cancer sensitivity to docetaxel via sponging miR-7. Cancer Cell International, 20, 334. https://doi.org/10.1186/s12935-020-01421-6CrossRefPubMedPubMedCentral

145.

Gu, H., & Duan, Z. (2022). Silencing of circDPP4 suppresses cell progression of human prostate cancer and enhances docetaxel cytotoxicity through regulating the miR-564/ZIC2 axis. The Journal Of Gene Medicine, 24, e3403. https://doi.org/10.1002/jgm.3403CrossRefPubMed

146.

Zheng, P., Gao, H., Xie, X., & Lu, P. (2022). Plasma exosomal hsa_circ_0015286 as a potential diagnostic and prognostic biomarker for gastric cancer. Pathology Oncology Research : POR, 28, 1610446. https://doi.org/10.3389/pore.2022.1610446CrossRefPubMedPubMedCentral

147.

Zheng, Y., Li, P., Ma, J., Yang, C., Dai, S., & Zhao, C. (2022). Cancer-derived exosomal circ_0038138 enhances glycolysis, growth, and metastasis of gastric adenocarcinoma via the miR-198/EZH2 axis. Translational Oncology, 25, 101479. https://doi.org/10.1016/j.tranon.2022.101479CrossRefPubMedPubMedCentral

148.

Tan, X., Song, X., Fan, B., Li, M., Zhang, A., & Pei, L. (2022). Exosomal circRNA Scm-like with four malignant brain tumor domains 2 (circ-SFMBT2) enhances the docetaxel resistance of prostate cancer via the microRNA-136-5p/tribbles homolog 1 pathway. Anti-Cancer Drugs, 33, 871–882. https://doi.org/10.1097/cad.0000000000001365CrossRefPubMed

149.

Chen, H., Li, H., & Chen, Q. (2016). INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer. Biochemical and Biophysical Research Communications, 477, 467–472. https://doi.org/10.1016/j.bbrc.2016.06.073CrossRefPubMed

150.

Ni, J., Cozzi, P., Hao, J., Beretov, J., Chang, L., Duan, W., Shigdar, S., Delprado, W., Graham, P., Bucci, J., et al. (2013). Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. The International Journal of Biochemistry & Cell Biology, 45, 2736–2748. https://doi.org/10.1016/j.biocel.2013.09.008CrossRef

151.

Sharma, P. K., Singh, R., Novakovic, K. R., Eaton, J. W., Grizzle, W. E., & Singh, S. (2010). CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. International Journal of Cancer, 127, 2020–2030. https://doi.org/10.1002/ijc.25219CrossRefPubMed

152.

Lee, J. T., Jr., Steelman, L. S., & McCubrey, J. A. (2004). Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer research, 64, 8397–8404. https://doi.org/10.1158/0008-5472.Can-04-1612CrossRefPubMed

153.

Hour, T. C., Chung, S. D., Kang, W. Y., Lin, Y. C., Chuang, S. J., Huang, A. M., Wu, W. J., Huang, S. P., Huang, C. Y., & Pu, Y. S. (2015). EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Archives of Toxicology, 89, 591–605. https://doi.org/10.1007/s00204-014-1275-xCrossRefPubMed

154.

Ni, J., Cozzi, P. J., Hao, J. L., Beretov, J., Chang, L., Duan, W., Shigdar, S., Delprado, W. J., Graham, P. H., Bucci, J., et al. (2014). CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. The Prostate, 74, 602–617. https://doi.org/10.1002/pros.22775CrossRefPubMed

155.

Zhou, W., Su, Y., Zhang, Y., Han, B., Liu, H., & Wang, X. (2020). Endothelial cells promote docetaxel resistance of prostate cancer cells by inducing ERG expression and activating Akt/mTOR signaling pathway. Frontiers in Oncology, 10, 584505. https://doi.org/10.3389/fonc.2020.584505CrossRefPubMedPubMedCentral

156.

Song, C., Zhang, J., Liu, X., Li, M., Wang, D., Kang, Z., Yu, J., Chen, J., Pan, H., Wang, H., et al. (2022). PTEN loss promotes Warburg effect and prostate cancer cell growth by inducing FBP1 degradation. Frontiers in Oncology, 12, 911466. https://doi.org/10.3389/fonc.2022.911466CrossRefPubMedPubMedCentral

157.

Ferraldeschi, R., Nava Rodrigues, D., Riisnaes, R., Miranda, S., Figueiredo, I., Rescigno, P., Ravi, P., Pezaro, C., Omlin, A., Lorente, D., et al. (2015). PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. European urology, 67, 795–802. https://doi.org/10.1016/j.eururo.2014.10.027CrossRefPubMedPubMedCentral

158.

Hong, Z., Wu, G., Xiang, Z. D., Xu, C. D., Huang, S. S., Li, C., Shi, L., & Wu, D. L. (2019). KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 114, 108793. https://doi.org/10.1016/j.biopha.2019.108793CrossRef

159.

Yuan, X. J., & Whang, Y. E. (2002). PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene, 21, 319–327. https://doi.org/10.1038/sj.onc.1205054CrossRefPubMed

160.

Huang, H., Cheville, J. C., Pan, Y., Roche, P. C., Schmidt, L. J., & Tindall, D. J. (2001). PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. The Journal of Biological Chemistry, 276, 38830–38836. https://doi.org/10.1074/jbc.M103632200CrossRefPubMed

161.

Zhao, W., Ning, L., Wang, L., Ouyang, T., Qi, L., Yang, R., & Wu, Y. (2021). miR-21 inhibition reverses doxorubicin-resistance and inhibits PC3 human prostate cancer cells proliferation. Andrologia, 53, e14016. https://doi.org/10.1111/and.14016CrossRefPubMed

162.

Sekino, Y., Han, X., Kawaguchi, T., Babasaki, T., Goto, K., Inoue, S., Hayashi, T., Teishima, J., Shiota, M., Yasui, W. et al. (2019). TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer. International Journal of Molecular Sciences, 20. https://doi.org/10.3390/ijms20163936

163.

Sekino, Y., Han, X., Babasaki, T., Miyamoto, S., Kobatake, K., Kitano, H., Ikeda, K., Goto, K., Inoue, S., Hayashi, T., et al. (2021). TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancer. Urologic Oncology, 39(368), e361-368.e369. https://doi.org/10.1016/j.urolonc.2021.03.001CrossRef

164.

Thalappil, M. A., Butturini, E., Carcereri de Prati, A., Bettin, I., Antonini, L., Sapienza, F. U., Garzoli, S., Ragno, R., Mariotto, S. (2022). Pinus mugo essential oil impairs STAT3 activation through oxidative stress and induces apoptosis in prostate cancer cells. Molecules (Basel, Switzerland), 27. https://doi.org/10.3390/molecules27154834

165.

Zhang, K., Yin, W., Ma, L., Liu, Z., & Li, Q. (2023). HSPB8 facilitates prostate cancer progression via activating the JAK/STAT3 signaling pathway. Biochemistry and Cell Biology = Biochimie et Biologie Cellulaire, 101, 1–11. https://doi.org/10.1139/bcb-2022-0205CrossRefPubMed

166.

Li, X., He, S., Liang, W., Zhang, W., Chen, X., Li, Q., Yang, X., Liu, Y., Zhu, D., Li, L., et al. (2023). Marsdenia tenacissima injection induces the apoptosis of prostate cancer by regulating the AKT/GSK3β/STAT3 signaling axis. Chinese Journal of Natural Medicines, 21, 113–126. https://doi.org/10.1016/s1875-5364(23)60389-9CrossRefPubMed

167.

Ji, Y., Liu, B., Chen, L., Li, A., Shen, K., Su, R., Zhang, W., Zhu, Y., Wang, Q., & Xue, W. (2023). Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway. Cellular Oncology (Dordrecht). https://doi.org/10.1007/s13402-023-00822-9CrossRefPubMed

168.

Zhong, W., Wu, K., Long, Z., Zhou, X., Zhong, C., Wang, S., Lai, H., Guo, Y., Lv, D., Lu, J., et al. (2022). Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome, 10, 94. https://doi.org/10.1186/s40168-022-01289-wCrossRefPubMedPubMedCentral

169.

Cheteh, E. H., Sarne, V., Ceder, S., Bianchi, J., Augsten, M., Rundqvist, H., Egevad, L., Östman, A., & Wiman, K. G. (2020). Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discovery, 6, 42. https://doi.org/10.1038/s41420-020-0272-5CrossRefPubMedPubMedCentral

170.

Liu, C., Zhu, Y., Lou, W., Cui, Y., Evans, C. P., & Gao, A. C. (2014). Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. The Prostate, 74, 201–209. https://doi.org/10.1002/pros.22741CrossRefPubMed

171.

Fu, Z., Zhao, P. Y., Yang, X. P., Li, H., Hu, S. D., Xu, Y. X., & Du, X. H. (2023). Cannabidiol regulates apoptosis and autophagy in inflammation and cancer: A review. Frontiers in Pharmacology, 14, 1094020. https://doi.org/10.3389/fphar.2023.1094020CrossRefPubMedPubMedCentral

172.

Thomas, S., & Shah, G. (2005). Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biology & Therapy, 4, 1226–1233. https://doi.org/10.4161/cbt.4.11.2093CrossRef

173.

Wu, G., Wang, J., Chen, G., & Zhao, X. (2017). microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1). American Journal of Translational Research, 9, 3599–3610.PubMedPubMedCentral

174.

Chen, L., Cai, J., Huang, Y., Tan, X., Guo, Q., Lin, X., Zhu, C., Zeng, X., Liu, H., & Wu, X. (2020). Identification of cofilin-1 as a novel mediator for the metastatic potentials and chemoresistance of the prostate cancer cells. European Journal of Pharmacology, 880, 173100. https://doi.org/10.1016/j.ejphar.2020.173100CrossRefPubMed

175.

Sun, M. Y., Xu, B., Wu, Q. X., Chen, W. L., Cai, S., Zhang, H., & Tang, Q. F. (2021). Cisplatin-resistant gastric cancer cells promote the chemoresistance of cisplatin-sensitive cells via the exosomal RPS3-mediated PI3K-Akt-Cofilin-1 signaling axis. Frontiers in Cell and Developmental Biology, 9, 618899. https://doi.org/10.3389/fcell.2021.618899CrossRefPubMedPubMedCentral

176.

Hsu, W. C., Ramesh, S., Shibu, M. A., Chen, M. C., Wang, T. F., Day, C. H., Chen, R. J., Padma, V. V., Li, C. C., Tseng, Y. C., et al. (2021). Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 82, 153442. https://doi.org/10.1016/j.phymed.2020.153442CrossRefPubMed

177.

Xiao, G., Wang, X., & Yu, Y. (2017). CXCR4/Let-7a axis regulates metastasis and chemoresistance of pancreatic cancer cells through targeting HMGA2. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 43, 840–851. https://doi.org/10.1159/000481610CrossRefPubMed

178.

Dong, J., Wang, R., Ren, G., Li, X., Wang, J., Sun, Y., Liang, J., Nie, Y., Wu, K., Feng, B., et al. (2017). HMGA2-FOXL2 axis regulates metastases and epithelial-to-mesenchymal transition of chemoresistant gastric cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23, 3461–3473. https://doi.org/10.1158/1078-0432.Ccr-16-2180CrossRefPubMed

179.

Cai, J., Shen, G., Liu, S., & Meng, Q. (2016). Downregulation of HMGA2 inhibits cellular proliferation and invasion, improves cellular apoptosis in prostate cancer. Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine, 37, 699–707. https://doi.org/10.1007/s13277-015-3853-9CrossRefPubMed

180.

Liu, Y., Xu, X., Lin, P., He, Y., Zhang, Y., Cao, B., Zhang, Z., Sethi, G., Liu, J., Zhou, X., et al. (2019). Inhibition of the deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis. The Journal of Biological Chemistry, 294, 4572–4582. https://doi.org/10.1074/jbc.RA118.006057CrossRefPubMedPubMedCentral

181.

Ye, Q. F., Zhang, Y. C., Peng, X. Q., Long, Z., Ming, Y. Z., & He, L. Y. (2012). siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells. Asian Pacific Journal of Cancer Prevention : APJCP, 13, 2485–2489. https://doi.org/10.7314/apjcp.2012.13.6.2485CrossRefPubMed

182.

Mancini, M. C. S., Morelli, A. P., Severino, M. B., Pavan, I. C. B., Zambalde, É. P., Góis, M. M., Silva, L., Quintero-Ruiz, N., Romeiro, C. F., Dos Santos, D. F. G., et al. (2022). Knockout of NRF2 triggers prostate cancer cells death through ROS modulation and sensitizes to cisplatin. Journal of Cellular Biochemistry, 123, 2079–2092. https://doi.org/10.1002/jcb.30333CrossRefPubMed

183.

Zhang, Y., Wang, Y., Yuan, J., Qin, W., Liu, F., Wang, F., Zhang, G., & Yang, X. (2012). Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells. Cell Biology and Toxicology, 28, 269–277. https://doi.org/10.1007/s10565-012-9221-2CrossRefPubMed

184.

Qian, S., Zhang, S., Wu, Y., Ding, Y., & Li, X. (2020). Protein disulfide isomerase 4 drives docetaxel resistance in prostate cancer. Chemotherapy, 65, 125–133. https://doi.org/10.1159/000511505CrossRefPubMed

185.

Liu, J., Chen, Z., Guo, J., Wang, L., Liu, X. (2019). Ambra1 induces autophagy and desensitizes human prostate cancer cells to cisplatin. Bioscience Reports, 39. https://doi.org/10.1042/bsr20170770

186.

Tang, Q., Fang, J., Lai, W., Hu, Y., Liu, C., Hu, X., Song, C., Cheng, T., Liu, R., & Huang, X. (2022). Hippo pathway monomerizes STAT3 to regulate prostate cancer growth. Cancer Science, 113, 2753–2762. https://doi.org/10.1111/cas.15463CrossRefPubMedPubMedCentral

187.

Sheng, W., Ding, J., Liu, L., Wang, N., Lu, B., You, X., He, Q., & Zhou, Q. (2022). Curcumol inhibits the development of prostate cancer by miR-125a/STAT3 axis. Evidence-based Complementary and Alternative Medicine : ECAM, 2022, 9317402. https://doi.org/10.1155/2022/9317402CrossRefPubMed

188.

Yu, C., Fan, Y., Zhang, Y., Liu, L., & Guo, G. (2022). LINC00893 inhibits the progression of prostate cancer through miR-3173-5p/SOCS3/JAK2/STAT3 pathway. Cancer Cell International, 22, 228. https://doi.org/10.1186/s12935-022-02637-4CrossRefPubMedPubMedCentral

189.

Hu, F., Zhao, Y., Yu, Y., Fang, J. M., Cui, R., Liu, Z. Q., Guo, X. L., & Xu, Q. (2018). Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3. Cancer Letters, 416, 24–30. https://doi.org/10.1016/j.canlet.2017.12.013CrossRefPubMed

190.

Chang, P. C., Wang, T. Y., Chang, Y. T., Chu, C. Y., Lee, C. L., Hsu, H. W., Zhou, T. A., Wu, Z., Kim, R. H., Desai, S. J., et al. (2014). Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells. PLoS ONE, 9, e88556. https://doi.org/10.1371/journal.pone.0088556CrossRefPubMedPubMedCentral

191.

Liao, H., Xiao, Y., Hu, Y., Xiao, Y., Yin, Z., Liu, L., Kang, X., & Chen, Y. (2016). Methylation-induced silencing of miR-34a enhances chemoresistance by directly upregulating ATG4B-induced autophagy through AMPK/mTOR pathway in prostate cancer. Oncology Reports, 35, 64–72. https://doi.org/10.3892/or.2015.4331CrossRefPubMed

192.

Zeng, J., Liu, W., Fan, Y. Z., He, D. L., & Li, L. (2018). PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy. Theranostics, 8, 109–123. https://doi.org/10.7150/thno.20356CrossRefPubMedPubMedCentral

193.

Xie, J., Chen, X., Wang, W., Guan, Z., Hou, J., & Lin, J. (2022). Long non-coding RNA PCDRlnc1 confers docetaxel resistance in prostate cancer by promoting autophagy. Journal of Cancer, 13, 2138–2149. https://doi.org/10.7150/jca.65329CrossRefPubMedPubMedCentral

194.

Lamprou, I., Tsolou, A., Kakouratos, C., Mitrakas, A. G., Xanthopoulou, E. T., Kassela, K., Karakasiliotis, I., Zois, C. E., Giatromanolaki, A., & Koukourakis, M. I. (2021). Suppressed PLIN3 frequently occurs in prostate cancer, promoting docetaxel resistance via intensified autophagy, an event reversed by chloroquine. Medical Oncology (Northwood, London, England), 38, 116. https://doi.org/10.1007/s12032-021-01566-yCrossRefPubMed

195.

Li, M., Chen, X., Wang, X., Wei, X., Wang, D., Liu, X., Xu, L., Batu, W., Li, Y., Guo, B., et al. (2021). RSL3 enhances the antitumor effect of cisplatin on prostate cancer cells via causing glycolysis dysfunction. Biochemical Pharmacology, 192, 114741. https://doi.org/10.1016/j.bcp.2021.114741CrossRefPubMed

196.

Martínez-Martínez, D., Soto, A., Gil-Araujo, B., Gallego, B., Chiloeches, A., & Lasa, M. (2019). Resveratrol promotes apoptosis through the induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association, 124, 273–279. https://doi.org/10.1016/j.fct.2018.12.014CrossRefPubMed

197.

Zhu, Q., Li, H., Liu, Y., & Jiang, L. (2017). Knockdown of CFTR enhances sensitivity of prostate cancer cells to cisplatin via inhibition of autophagy. Neoplasma, 64, 709–717. https://doi.org/10.4149/neo_2017_508CrossRefPubMed

198.

Kim, K. Y., Yun, U. J., Yeom, S. H., Kim, S. C., Lee, H. J., Ahn, S.C., Park, K. I., Kim, Y. W. (2021). Inhibition of autophagy promotes hemistepsin A-induced apoptosis via reactive oxygen species-mediated AMPK-dependent signaling in human prostate cancer cells. Biomolecules, 11. https://doi.org/10.3390/biom11121806

199.

Lin, J. Z., Wang, W. W., Hu, T. T., Zhu, G. Y., Li, L. N., Zhang, C. Y., Xu, Z., Yu, H. B., Wu, H. F., & Zhu, J. G. (2020). FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy. Cancer Letters, 469, 481–489. https://doi.org/10.1016/j.canlet.2019.11.014CrossRefPubMed

200.

Chen, Z., Jiang, Q., Zhu, P., Chen, Y., Xie, X., Du, Z., Jiang, L., & Tang, W. (2019). NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer. The Prostate, 79, 44–53. https://doi.org/10.1002/pros.23709CrossRefPubMed

201.

Chen, J., Xu, D., Wang, T., Yang, Z., Yang, Y., He, K., Zhao, L. (2022). HMGB1 promotes the development of castration‑resistant prostate cancer by regulating androgen receptor activation. Oncology Reports, 48. https://doi.org/10.3892/or.2022.8412

202.

Lv, D. J., Song, X. L., Huang, B., Yu, Y. Z., Shu, F. P., Wang, C., Chen, H., Zhang, H. B., & Zhao, S. C. (2019). HMGB1 promotes prostate cancer development and metastasis by interacting with Brahma-related gene 1 and activating the Akt signaling pathway. Theranostics, 9, 5166–5182. https://doi.org/10.7150/thno.33972CrossRefPubMedPubMedCentral

203.

Jung, A. R., Kim, G. E., Kim, M. Y., Ha, U. S., Hong, S. H., Lee, J. Y., Kim, S. W., & Park, Y. H. (2021). HMGB1 promotes tumor progression and invasion through HMGB1/TNFR1/NF-κB axis in castration-resistant prostate cancer. American Journal of Cancer Research, 11, 2215–2227.PubMedPubMedCentral

204.

Zhang, Y. X., Yuan, Y. Q., Zhang, X. Q., Huang, D. L., Wei, Y. Y., & Yang, J. G. (2017). HMGB1-mediated autophagy confers resistance to gemcitabine in hormone-independent prostate cancer cells. Oncology Letters, 14, 6285–6290. https://doi.org/10.3892/ol.2017.6965CrossRefPubMedPubMedCentral

205.

Yu, Y., Yang, F. H., Zhang, W. T., Guo, Y. D., Ye, L., & Yao, X. D. (2021). Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy. Cell & Bioscience, 11, 7. https://doi.org/10.1186/s13578-020-00494-0CrossRef

206.

Wang, Q., He, W. Y., Zeng, Y. Z., Hossain, A., & Gou, X. (2018). Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells. International Urology and Nephrology, 50, 675–686. https://doi.org/10.1007/s11255-018-1801-5CrossRefPubMedPubMedCentral

207.

Nguyen, H. G., Yang, J. C., Kung, H. J., Shi, X. B., Tilki, D., Lara, P. N., Jr., DeVere White, R. W., Gao, A. C., & Evans, C. P. (2014). Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene, 33, 4521–4530. https://doi.org/10.1038/onc.2014.25CrossRefPubMedPubMedCentral

208.

Peng, K., Sun, A., Zhu, J., Gao, J., Li, Y., Shao, G., Yang, W., & Lin, Q. (2021). Restoration of the ATG5-dependent autophagy sensitizes DU145 prostate cancer cells to chemotherapeutic drugs. Oncology Letters, 22, 638. https://doi.org/10.3892/ol.2021.12899CrossRefPubMedPubMedCentral

209.

Mortezavi, A., Salemi, S., Kranzbühler, B., Gross, O., Sulser, T., Simon, H. U., & Eberli, D. (2019). Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancer. World Journal of Urology, 37, 351–358. https://doi.org/10.1007/s00345-018-2385-5CrossRefPubMed

210.

Losada-García, A., Salido-Guadarrama, I., Cortes-Ramirez, S. A., Cruz-Burgos, M., Morales-Pacheco, M., Vazquez-Santillan, K., Rodriguez-Martinez, G., González-Ramírez, I., Gonzalez-Covarrubias, V., Perez-Plascencia, C., et al. (2023). SFRP1 induces a stem cell phenotype in prostate cancer cells. Frontiers in Cell and Developmental Biology, 11, 1096923. https://doi.org/10.3389/fcell.2023.1096923CrossRefPubMedPubMedCentral

211.

Song, X. L., Huang, B., Zhou, B. W., Wang, C., Liao, Z. W., Yu, Y., & Zhao, S. C. (2018). miR-1301–3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3β. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 99, 369–374. https://doi.org/10.1016/j.biopha.2018.01.086CrossRef

212.

Pérez, G., López-Moncada, F., Indo, S., Torres, M. J., Castellón, E. A., Contreras, H. R. (2021). Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells. Oncology Reports, 45. https://doi.org/10.3892/or.2021.8009

213.

Cheng, J. W., Duan, L. X., Yu, Y., Wang, P., Feng, J. L., Feng, G. Z., & Liu, Y. (2021). Bone marrow mesenchymal stem cells promote prostate cancer cell stemness via cell-cell contact to activate the Jagged1/Notch1 pathway. Cell & Bioscience, 11, 87. https://doi.org/10.1186/s13578-021-00599-0CrossRef

214.

Zhang, Y., He, L., Sadagopan, A., Ma, T., Dotti, G., Wang, Y., Zheng, H., Gao, X., Wang, D., DeLeo, A. B., et al. (2021). Targeting radiation-resistant prostate cancer stem cells by B7–H3 CAR T cells. Molecular Cancer Therapeutics, 20, 577–588. https://doi.org/10.1158/1535-7163.mct-20-0446CrossRefPubMedPubMedCentral

215.

Castellón, E. A., Indo, S., Contreras, H. R. (2022). Cancer stemness/epithelial-mesenchymal transition axis influences metastasis and castration resistance in prostate cancer: Potential therapeutic target. International Journal of Molecular Sciences, 23. https://doi.org/10.3390/ijms232314917

216.

Li, P., Yang, R., & Gao, W. Q. (2014). Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Molecular Cancer, 13, 55. https://doi.org/10.1186/1476-4598-13-55CrossRefPubMedPubMedCentral

217.

Yan, J., & Tang, D. (2014). Prostate cancer stem-like cells proliferate slowly and resist etoposide-induced cytotoxicity via enhancing DNA damage response. Experimental Cell Research, 328, 132–142. https://doi.org/10.1016/j.yexcr.2014.08.016CrossRefPubMed

218.

Jeter, C. R., Liu, B., Liu, X., Chen, X., Liu, C., Calhoun-Davis, T., Repass, J., Zaehres, H., Shen, J. J., & Tang, D. G. (2011). NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene, 30, 3833–3845. https://doi.org/10.1038/onc.2011.114CrossRefPubMedPubMedCentral

219.

Ramesh, V., Brabletz, T., & Ceppi, P. (2020). Targeting EMT in cancer with repurposed metabolic inhibitors. Trends in Cancer, 6, 942–950. https://doi.org/10.1016/j.trecan.2020.06.005CrossRefPubMed

220.

Guo, Z., Ashrafizadeh, M., Zhang, W., Zou, R., Sethi, G., & Zhang, X. (2023). Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: A pre-clinical connection to aggressiveness and drug resistance. Cancer Metastasis Reviews. https://doi.org/10.1007/s10555-023-10125-yCrossRefPubMed

221.

He, P., Dai, Q., & Wu, X. (2023). New insight in urological cancer therapy: From epithelial-mesenchymal transition (EMT) to application of nano-biomaterials. Environmental Research, 229, 115672. https://doi.org/10.1016/j.envres.2023.115672CrossRefPubMed

222.

Zhang, Z. H., Liu, M. D., Yao, K., Xu, S., Yu, D. X., Xie, D. D., & Xu, D. X. (2023). Vitamin D deficiency aggravates growth and metastasis of prostate cancer through promoting EMT in two β-catenin-related mechanisms. The Journal of Nutritional Biochemistry, 111, 109177. https://doi.org/10.1016/j.jnutbio.2022.109177CrossRefPubMed

223.

Qiao, P., & Tian, Z. (2022). Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27. Frontiers in Oncology, 12, 1084884. https://doi.org/10.3389/fonc.2022.1084884CrossRefPubMed

224.

Pang, X., Zhang, J., He, X., Gu, Y., Qian, B. Z., Xie, R., Yu, W., Zhang, X., Li, T., Shi, X., et al. (2021). SPP1 promotes enzalutamide resistance and epithelial-mesenchymal-transition activation in castration-resistant prostate cancer via PI3K/AKT and ERK1/2 pathways. Oxidative Medicine and Cellular Longevity, 2021, 5806602. https://doi.org/10.1155/2021/5806602CrossRefPubMedPubMedCentral

225.

Chen, B., Zhang, Y., Li, C., Xu, P., Gao, Y., & Xu, Y. (2021). CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer. Archives of Medical Science : AMS, 17, 152–165. https://doi.org/10.5114/aoms.2020.92939CrossRefPubMed

226.

Rajput, M., Singh, R., Singh, N., & Singh, R. P. (2021). EGFR-mediated Rad51 expression potentiates intrinsic resistance in prostate cancer via EMT and DNA repair pathways. Life Sciences, 286, 120031. https://doi.org/10.1016/j.lfs.2021.120031CrossRefPubMed

227.

Choi, J. D., Kim, T. J., Jeong, B. C., Jeon, H. G., Jeon, S. S., Kang, M. Y., Yeom, S. Y., & Seo, S. I. (2021). ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT). Scientific Reports, 11, 21984. https://doi.org/10.1038/s41598-021-01003-0CrossRefPubMedPubMedCentral

228.

Zhang, B., Li, Y., Wu, Q., Xie, L., Barwick, B., Fu, C., Li, X., Wu, D., Xia, S., Chen, J., et al. (2021). Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nature Communications, 12, 1714. https://doi.org/10.1038/s41467-021-21976-wCrossRefPubMedPubMedCentral

229.

Chen, D., Chou, F. J., Chen, Y., Huang, C. P., Tian, H., Wang, Y., Niu, Y., You, B., Yeh, S., Xing, N., et al. (2022). Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity. Journal of Experimental & Clinical Cancer Research : CR, 41, 235. https://doi.org/10.1186/s13046-022-02287-4CrossRefPubMedCentral

230.

Zhang, X., Huang, J., Yu, C., Xiang, L., Li, L., Shi, D., & Lin, F. (2020). Quercetin enhanced paclitaxel therapeutic effects towards PC-3 prostate cancer through ER stress induction and ROS production. OncoTargets and Therapy, 13, 513–523. https://doi.org/10.2147/ott.S228453CrossRefPubMedPubMedCentral

231.

Shu, Y., Xie, B., Liang, Z., & Chen, J. (2018). Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met. Oncology Letters, 15, 2252–2258. https://doi.org/10.3892/ol.2017.7561CrossRefPubMed

232.

Lu, X., Yang, F., Chen, D., Zhao, Q., Chen, D., Ping, H., & Xing, N. (2020). Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. International Journal of Biological Sciences, 16, 1121–1134. https://doi.org/10.7150/ijbs.41686CrossRefPubMedPubMedCentral

233.

Serttas, R., Koroglu, C., & Erdogan, S. (2021). Eupatilin inhibits the proliferation and migration of prostate cancer cells through modulation of PTEN and NF-κB signaling. Anti-cancer Agents in Medicinal Chemistry, 21, 372–382. https://doi.org/10.2174/1871520620666200811113549CrossRefPubMed

234.

Wang, P., Henning, S. M., Heber, D., & Vadgama, J. V. (2015). Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. The Journal of Nutritional Biochemistry, 26, 408–415. https://doi.org/10.1016/j.jnutbio.2014.11.017CrossRefPubMedPubMedCentral

235.

Bao, X., Zhu, J., Ren, C., Zhao, A., Zhang, M., Zhu, Z., Lu, X., Zhang, Y., Li, X., Sima, X., et al. (2021). β-elemonic acid inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells through the suppression of JAK2/STAT3/MCL-1 and NF-ĸB signal pathways. Chemico-Biological Interactions, 342, 109477. https://doi.org/10.1016/j.cbi.2021.109477CrossRefPubMed

236.

Liu, Y. Q., Wang, S. K., Xu, Q. Q., Yuan, H. Q., Guo, Y. X., Wang, Q., Kong, F., Lin, Z. M., Sun, D. Q., Wang, R. M., et al. (2019). Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties. Acta Pharmacologica Sinica, 40, 689–698. https://doi.org/10.1038/s41401-018-0157-9CrossRefPubMed

237.

Cao, H., Wang, D., Gao, R., Feng, Y., & Chen, L. (2022). Qi Ling decreases paclitaxel resistance in the human prostate cancer by reversing tumor-associated macrophages function. Aging, 14, 1812–1821. https://doi.org/10.18632/aging.203904CrossRefPubMedPubMedCentral

238.

Thaper, D., Vahid, S., Kaur, R., Kumar, S., Nouruzi, S., Bishop, J. L., Johansson, M., & Zoubeidi, A. (2018). Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer. Scientific Reports, 8, 17307. https://doi.org/10.1038/s41598-018-35612-zCrossRefPubMedPubMedCentral

239.

Liu, Q., Tong, D., Liu, G., Xu, J., Do, K., Geary, K., Zhang, D., Zhang, J., Zhang, Y., Li, Y., et al. (2017). Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT. Cell Death & Disease, 8, e3007. https://doi.org/10.1038/cddis.2017.417CrossRef

240.

Ge, J., Wang, P., Ma, H., & Zhang, J. (2022). Solamargine inhibits prostate cancer cell growth and enhances the therapeutic efficacy of docetaxel via Akt signaling. Journal of Oncology, 2022, 9055954. https://doi.org/10.1155/2022/9055954CrossRefPubMedPubMedCentral

241.

Erdogan, S., Turkekul, K., Serttas, R., & Erdogan, Z. (2017). The natural flavonoid apigenin sensitizes human CD44(+) prostate cancer stem cells to cisplatin therapy. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 88, 210–217. https://doi.org/10.1016/j.biopha.2017.01.056CrossRef

242.

Thamilselvan, V., Menon, M., & Thamilselvan, S. (2011). Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway. International Journal of Cancer, 129, 2916–2927. https://doi.org/10.1002/ijc.25949CrossRefPubMed

243.

Hellsten, R., Stiehm, A., Palominos, M., Persson, M., & Bjartell, A. (2022). The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells. Translational Oncology, 24, 101495. https://doi.org/10.1016/j.tranon.2022.101495CrossRefPubMedPubMedCentral

244.

Liu, C., Lou, W., Armstrong, C., Zhu, Y., Evans, C. P., & Gao, A. C. (2015). Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. The Prostate, 75, 1341–1353. https://doi.org/10.1002/pros.23015CrossRefPubMedPubMedCentral

245.

Chen, Y., Gera, L., Zhang, S., Li, X., Yang, Y., Mamouni, K., Wu, A. Y., Liu, H., Kucuk, O., & Wu, D. (2019). Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models. Cancer Letters, 446, 62–72. https://doi.org/10.1016/j.canlet.2019.01.010CrossRefPubMedPubMedCentral

246.

Imrali, A., Mao, X., Yeste-Velasco, M., Shamash, J., & Lu, Y. (2016). Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin. American Journal of Cancer Research, 6, 1772–1784.PubMedPubMedCentral

247.

Alshaker, H., Wang, Q., Kawano, Y., Arafat, T., Böhler, T., Winkler, M., Cooper, C., & Pchejetski, D. (2016). Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1. Oncotarget, 7, 80943–80956. https://doi.org/10.18632/oncotarget.13115CrossRefPubMedPubMedCentral

248.

Luo, Y., Li, M., Zuo, X., Basourakos, S. P., Zhang, J., Zhao, J., Han, Y., Lin, Y., Wang, Y., Jiang, Y., et al. (2018). β-catenin nuclear translocation induced by HIF-1α overexpression leads to the radioresistance of prostate cancer. International Journal of Oncology, 52, 1827–1840. https://doi.org/10.3892/ijo.2018.4368CrossRefPubMedPubMedCentral

249.

Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., Wu, H., Bova, S. G., & Biswal, S. (2010). Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Molecular Cancer Therapeutics, 9, 336–346. https://doi.org/10.1158/1535-7163.Mct-09-0589CrossRefPubMedPubMedCentral

250.

Huang, Z. C., Huang, J., Huang, C. K., Hou, Y., & Zhu, B. (2023). Euchromatic histone lysine methyltransferase 2 facilitates radioresistance in prostate cancer by repressing endoplasmic reticulum protein 29 transcription. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12661CrossRefPubMed

251.

El Bezawy, R., Tinelli, S., Tortoreto, M., Doldi, V., Zuco, V., Folini, M., Stucchi, C., Rancati, T., Valdagni, R., Gandellini, P., et al. (2019). miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCε and ZEB1 inhibition. Journal of Experimental & Clinical Cancer Research : CR, 38, 51. https://doi.org/10.1186/s13046-019-1060-zCrossRefPubMedPubMedCentral

252.

Marampon, F., Gravina, G., Ju, X., Vetuschi, A., Sferra, R., Casimiro, M., Pompili, S., Festuccia, C., Colapietro, A., Gaudio, E., et al. (2016). Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage. Oncotarget, 7, 5383–5400. https://doi.org/10.18632/oncotarget.6579CrossRefPubMed

253.

Wu, K., Wu, M., Yang, H., Diao, R., & Zeng, H. (2023). Hypoxia promotes conversion to a stem cell phenotype in prostate cancer cells by activating HIF-1α/Notch1 signaling pathway. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. https://doi.org/10.1007/s12094-023-03093-wCrossRef

254.

Owari, T., Tanaka, N., Nakai, Y., Miyake, M., Anai, S., Kishi, S., Mori, S., Fujiwara-Tani, R., Hojo, Y., Mori, T., et al. (2022). 5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells. British Journal of Cancer, 127, 350–363. https://doi.org/10.1038/s41416-022-01789-4CrossRefPubMedPubMedCentral

255.

Gu, H., Liu, M., Ding, C., Wang, X., Wang, R., Wu, X., & Fan, R. (2016). Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1. Cancer Medicine, 5, 1174–1182. https://doi.org/10.1002/cam4.664CrossRefPubMedPubMedCentral

256.

Shang, Z. F., Wei, Q., Yu, L., Huang, F., Xiao, B. B., Wang, H., Song, M., Wang, L., Zhou, J., Wang, J., et al. (2016). Suppression of PC-1/PrLZ sensitizes prostate cancer cells to ionizing radiation by attenuating DNA damage repair and inducing autophagic cell death. Oncotarget, 7, 62340–62351. https://doi.org/10.18632/oncotarget.11470CrossRefPubMedPubMedCentral

257.

Schwarz, F. M., Schniewind, I., Besso, M. J., Lange, S., Linge, A., Patil, S. G., Löck, S., Klusa, D., Dietrich, A., Voss-Böhme, A., et al. (2022). Plasticity within aldehyde dehydrogenase-positive cells determines prostate cancer radiosensitivity. Molecular Cancer Research : MCR, 20, 794–809. https://doi.org/10.1158/1541-7786.Mcr-21-0806CrossRefPubMed

258.

Xu, Z., Zhang, Y., Ding, J., Hu, W., Tan, C., Wang, M., Tang, J., & Xu, Y. (2018). miR-17-3p Downregulates mitochondrial antioxidant enzymes and enhances the radiosensitivity of prostate cancer cells. Molecular Therapy. Nucleic Acids, 13, 64–77. https://doi.org/10.1016/j.omtn.2018.08.009CrossRefPubMedPubMedCentral

259.

Fan, Y., Fan, H., Quan, Z., & Wu, X. (2021). Ionizing radiation combined with PARP1 inhibitor reduces radioresistance in prostate cancer with RB1/TP53 loss. Cancer Investigation, 39, 423–434. https://doi.org/10.1080/07357907.2021.1899200CrossRefPubMed

260.

Pawar, J. S., Al-Amin, M. Y., & Hu, C. D. (2023). JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer. Frontiers in Oncology, 13, 1126482. https://doi.org/10.3389/fonc.2023.1126482CrossRefPubMedPubMedCentral

261.

He, Z., Yuan, J., Shen, F., Zeng, F., Qi, P., Wang, Z., & Zhai, Z. (2020). Atorvastatin enhances effects of radiotherapy on prostate cancer cells and xenograft tumor mice through triggering interaction between Bcl-2 and MSH2. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 26, e923560. https://doi.org/10.12659/msm.923560CrossRefPubMed

262.

Rajput, M., Mishra, D., Kumar, K., & Singh, R. P. (2022). Silibinin radiosensitizes EGF receptor-knockdown prostate cancer cells by attenuating DNA repair pathways. Journal of Cancer Prevention, 27, 170–181. https://doi.org/10.15430/jcp.2022.27.3.170CrossRefPubMedPubMedCentral

263.

Li, J., Wang, Z., Li, H., Cao, J., Nan, N., Zhai, X., Liu, Y., & Chong, T. (2022). Resveratrol inhibits TRAF6/PTCH/SMO signal and regulates prostate cancer progression. Cytotechnology, 74, 549–558. https://doi.org/10.1007/s10616-022-00544-0CrossRefPubMedPubMedCentral

264.

Zhang, L., Lin, Z., Chen, Y., Gao, D., Wang, P., Lin, Y., Wang, Y., Wang, F., Han, Y., & Yuan, H. (2022). Co-delivery of Docetaxel and Resveratrol by liposomes synergistically boosts antitumor efficiency against prostate cancer. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 174, 106199. https://doi.org/10.1016/j.ejps.2022.106199CrossRefPubMed

265.

Han, D. S., Lee, H. J., & Lee, E. O. (2022). Resveratrol suppresses serum-induced vasculogenic mimicry through impairing the EphA2/twist-VE-cadherin/AKT pathway in human prostate cancer PC-3 cells. Scientific Reports, 12, 20125. https://doi.org/10.1038/s41598-022-24414-zCrossRefPubMedPubMedCentral

266.

Fang, Y., DeMarco, V. G., & Nicholl, M. B. (2012). Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Science, 103, 1090–1098. https://doi.org/10.1111/j.1349-7006.2012.02272.xCrossRefPubMedPubMedCentral

267.

Zhang, T., Zhang, L., Zhang, T., Fan, J., Wu, K., Guan, Z., Wang, X., Li, L., Hsieh, J. T., He, D., et al. (2014). Metformin sensitizes prostate cancer cells to radiation through EGFR/p-DNA-PKCS in vitro and in vivo. Radiation Research, 181, 641–649. https://doi.org/10.1667/rr13561.1CrossRefPubMed

268.

Potiron, V. A., Abderrahmani, R., Giang, E., Chiavassa, S., Di Tomaso, E., Maira, S. M., Paris, F., & Supiot, S. (2013). Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 106, 138–146. https://doi.org/10.1016/j.radonc.2012.11.014CrossRefPubMed

269.

Zhang, Y., Xu, Z., Ding, J., Tan, C., Hu, W., Li, Y., Huang, W., & Xu, Y. (2018). HZ08 suppresses RelB-activated MnSOD expression and enhances radiosensitivity of prostate cancer cells. Journal of Experimental & Clinical Cancer Research : CR, 37, 174. https://doi.org/10.1186/s13046-018-0849-5CrossRefPubMedCentral

270.

Chen, Y. A., Tzeng, D. T. W., Huang, Y. P., Lin, C. J., Lo, U. G., Wu, C. L., Lin, H., Hsieh, J. T., Tang, C. H., Lai, C. H. (2018). Antrocin sensitizes prostate cancer cells to radiotherapy through inhibiting PI3K/AKT and MAPK signaling pathways. Cancers, 11. https://doi.org/10.3390/cancers11010034

271.

Ma, X., Wang, Z., Ren, H., Bao, X., Zhang, Y., Wang, B., & Ruan, D. (2020). Long non-coding RNA GAS5 suppresses tumor progression and enhances the radiosensitivity of prostate cancer through the miR-320a/RAB21 axis. Cancer Management and Research, 12, 8833–8845. https://doi.org/10.2147/cmar.S244123CrossRefPubMedPubMedCentral

272.

Zhu, L., Zhu, B., Yang, L., Zhao, X., Jiang, H., & Ma, F. (2014). RelB regulates Bcl-xl expression and the irradiation-induced apoptosis of murine prostate cancer cells. Biomedical Reports, 2, 354–358. https://doi.org/10.3892/br.2014.250CrossRefPubMedPubMedCentral

273.

Fan, L., Xu, S., Zhang, F., Cui, X., Fazli, L., Gleave, M., Clark, D. J., Yang, A., Hussain, A., Rassool, F., et al. (2020). Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells. Cell Death & Disease, 11, 214. https://doi.org/10.1038/s41419-020-2405-4CrossRef

274.

Chang, L., Graham, P. H., Hao, J., Ni, J., Bucci, J., Cozzi, P. J., Kearsley, J. H., & Li, Y. (2014). PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death & Disease, 5, e1437. https://doi.org/10.1038/cddis.2014.415CrossRef

275.

Chen, Y. Y., Luo, L. P., & Deng, K. C. (2023). Circular RNA LPAR3 targets JPT1 via microRNA-513b-5p to facilitate glycolytic activation but repress prostate cancer radiosensitivity. Acta Biochimica Polonica, 70, 153–162. https://doi.org/10.18388/abp.2020_6379CrossRefPubMed

276.

Hoey, C., Ray, J., Jeon, J., Huang, X., Taeb, S., Ylanko, J., Andrews, D. W., Boutros, P. C., & Liu, S. K. (2018). miRNA-106a and prostate cancer radioresistance: A novel role for LITAF in ATM regulation. Molecular Oncology, 12, 1324–1341. https://doi.org/10.1002/1878-0261.12328CrossRefPubMedPubMedCentral

277.

Chen, X., Chen, F., Ren, Y., Weng, G., Keng, P. C., Chen, Y., & Lee, S. O. (2019). Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer. The Prostate, 79, 1386–1398. https://doi.org/10.1002/pros.23861CrossRefPubMed

278.

Wang, W., Liu, M., Guan, Y., & Wu, Q. (2016). Hypoxia-responsive Mir-301a and Mir-301b promote radioresistance of prostate cancer cells via downregulating NDRG2. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 22, 2126–2132. https://doi.org/10.12659/msm.896832CrossRefPubMed

279.

Kajanne, R., Miettinen, P., Tenhunen, M., & Leppä, S. (2009). Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells. International Journal of Oncology, 35, 1175–1182. https://doi.org/10.3892/ijo_00000434CrossRefPubMed

280.

Du, S., Zhang, P., Ren, W., Yang, F., & Du, C. (2020). Circ-ZNF609 accelerates the radioresistance of prostate cancer cells by promoting the glycolytic metabolism through miR-501-3p/HK2 axis. Cancer Management and Research, 12, 7487–7499. https://doi.org/10.2147/cmar.S257441CrossRefPubMedPubMedCentral

281.

Wang, T., Huang, J., Vue, M., Alavian, M. R., Goel, H. L., Altieri, D. C., Languino, L. R., & FitzGerald, T. J. (2019). α(v)β(3) Integrin mediates radioresistance of prostate cancer cells through regulation of survivin. Molecular Cancer Research : MCR, 17, 398–408. https://doi.org/10.1158/1541-7786.Mcr-18-0544CrossRefPubMed

282.

Broustas, C. G., Duval, A. J., Chaudhary, K. R., Friedman, R. A., Virk, R. K., & Lieberman, H. B. (2020). Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents. Oncogene, 39, 2467–2477. https://doi.org/10.1038/s41388-020-1163-1CrossRefPubMedPubMedCentral

283.

Yao, B., Liu, B., Shi, L., Li, X., Ren, C., Cai, M., Wang, W., Li, J., Sun, Y., Wu, Y., et al. (2017). PAFR selectively mediates radioresistance and irradiation-induced autophagy suppression in prostate cancer cells. Oncotarget, 8, 13846–13854. https://doi.org/10.18632/oncotarget.14647CrossRefPubMedPubMedCentral

284.

Ciccarelli, C., Di Rocco, A., Gravina, G. L., Mauro, A., Festuccia, C., Del Fattore, A., Berardinelli, P., De Felice, F., Musio, D., Bouché, M., et al. (2018). Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 144, 1685–1699. https://doi.org/10.1007/s00432-018-2696-3CrossRefPubMed

285.

Chen, X., Chen, F., Ren, Y., Weng, G., Xu, L., Xue, X., Keng, P. C., Lee, S. O., & Chen, Y. (2019). IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. Journal of Cancer Research and Clinical Oncology, 145, 1471–1484. https://doi.org/10.1007/s00432-019-02917-zCrossRefPubMed

286.

Ruan, H., Bao, L., Tao, Z., & Chen, K. (2021). Flightless I homolog reverses enzalutamide resistance through PD-L1-mediated immune evasion in prostate cancer. Cancer Immunology Research, 9, 838–852. https://doi.org/10.1158/2326-6066.Cir-20-0729CrossRefPubMed

287.

Kolijn, K., Verhoef, E. I., Smid, M., Böttcher, R., Jenster, G. W., Debets, R., & van Leenders, G. (2018). Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression. Cancer Research, 78, 4671–4679. https://doi.org/10.1158/0008-5472.Can-17-3752CrossRefPubMed

288.

Chen, Q. H., Li, B., Liu, D. G., Zhang, B., Yang, X., & Tu, Y. L. (2020). LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1. Cancer Cell International, 20, 394. https://doi.org/10.1186/s12935-020-01481-8CrossRefPubMedPubMedCentral

289.

Kan, L., Huang, Y., Liu, Z. (2023). JUN and ATF3 are deficient in prostate cancer patients and their delivery in vivo via lipid nanoparticles has therapeutic efficacy by enhancing immune surveillance. Pharmacological Research, 106753. https://doi.org/10.1016/j.phrs.2023.106753

290.

Drehmer, D., Mesquita Luiz, J. P., Hernandez, C. A. S., Alves-Filho, J. C., Hussell, T., Townsend, P. A., & Moncada, S. (2022). Nitric oxide favours tumour-promoting inflammation through mitochondria-dependent and -independent actions on macrophages. Redox Biology, 54, 102350. https://doi.org/10.1016/j.redox.2022.102350CrossRefPubMedPubMedCentral

291.

Won, H., Moreira, D., Gao, C., Duttagupta, P., Zhao, X., Manuel, E., Diamond, D., Yuan, Y. C., Liu, Z., Jones, J., et al. (2017). TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. Journal of Leukocyte Biology, 102, 423–436. https://doi.org/10.1189/jlb.3MA1016-451RRCrossRefPubMedPubMedCentral

292.

Groeger, S., Wu, F., Wagenlehner, F., Dansranjav, T., Ruf, S., Denter, F., & Meyle, J. (2022). PD-L1 up-regulation in prostate cancer cells by Porphyromonas gingivalis. Frontiers in Cellular and Infection Microbiology, 12, 935806. https://doi.org/10.3389/fcimb.2022.935806CrossRefPubMedPubMedCentral

293.

Li, N., Liu, Q., Han, Y., Pei, S., Cheng, B., Xu, J., Miao, X., Pan, Q., Wang, H., Guo, J., et al. (2022). ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nature Communications, 13, 7281. https://doi.org/10.1038/s41467-022-34871-9CrossRefPubMedPubMedCentral

294.

Imamura, R., Kitagawa, S., Kubo, T., Irie, A., Kariu, T., Yoneda, M., Kamba, T., & Imamura, T. (2021). Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a. The Prostate, 81, 147–156. https://doi.org/10.1002/pros.24090CrossRefPubMed

295.

Zhang, Y., Zhu, S., Du, Y., Xu, F., Sun, W., Xu, Z., Wang, X., Qian, P., Zhang, Q., Feng, J., et al. (2022). RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. Journal of Experimental & Clinical Cancer Research : CR, 41, 66. https://doi.org/10.1186/s13046-022-02243-2CrossRefPubMedCentral

296.

Wise, D. R., Schneider, J.A., Armenia, J., Febles, V. A., McLaughlin, B., Brennan, R., Thoren, K. L., Abida, W., Sfanos, K. S., De Marzo, A. M., et al. (2020). Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer. JCO Precision Oncology, 4. https://doi.org/10.1200/po.20.00097

297.

Su, W., Han, H. H., Wang, Y., Zhang, B., Zhou, B., Cheng, Y., Rumandla, A., Gurrapu, S., Chakraborty, G., Su, J., et al. (2019). The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell, 36, 139-155.e110. https://doi.org/10.1016/j.ccell.2019.06.009CrossRefPubMedPubMedCentral

298.

Bancaro, N., Calì, B., Troiani, M., Elia, A. R., Arzola, R. A., Attanasio, G., Lai, P., Crespo, M., Gurel, B., Pereira, R., et al. (2023). Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer Cell, 41, 602-619.e611. https://doi.org/10.1016/j.ccell.2023.02.004CrossRefPubMed

299.

Moon, S. J., Jeong, B. C., Kim, H. J., Lim, J. E., Kim, H. J., Kwon, G. Y., Jackman, J. A., & Kim, J. H. (2021). Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer. Theranostics, 11, 958–973. https://doi.org/10.7150/thno.51478CrossRefPubMedPubMedCentral

300.

Castilla, C., Congregado, B., Conde, J. M., Medina, R., Torrubia, F. J., Japón, M. A., & Sáez, C. (2010). Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer. Urology, 76(1017), e1011-1016. https://doi.org/10.1016/j.urology.2010.05.045CrossRef

301.

Karantanos, T., Karanika, S., Wang, J., Yang, G., Dobashi, M., Park, S., Ren, C., Li, L., Basourakos, S. P., Hoang, A., et al. (2016). Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget, 7, 46321–46334. https://doi.org/10.18632/oncotarget.10113CrossRefPubMedPubMedCentral

302.

Zhang, Y., Linn, D., Liu, Z., Melamed, J., Tavora, F., Young, C. Y., Burger, A. M., & Hamburger, A. W. (2008). EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Molecular Cancer Therapeutics, 7, 3176–3186. https://doi.org/10.1158/1535-7163.Mct-08-0526CrossRefPubMedPubMedCentral

303.

Castilla, C., Congregado, B., Chinchón, D., Torrubia, F. J., Japón, M. A., & Sáez, C. (2006). Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology, 147, 4960–4967. https://doi.org/10.1210/en.2006-0502CrossRefPubMed

304.

Wilkinson, S., Ye, H., Karzai, F., Harmon, S. A., Terrigino, N. T., VanderWeele, D. J., Bright, J. R., Atway, R., Trostel, S. Y., Carrabba, N. V., et al. (2021). Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy. European Urology, 80, 746–757. https://doi.org/10.1016/j.eururo.2021.03.009CrossRefPubMedPubMedCentral

305.

Cheng, Q., Butler, W., Zhou, Y., Zhang, H., Tang, L., Perkinson, K., Chen, X., Jiang, X. S., McCall, S. J., Inman, B. A., et al. (2022). Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy. European Urology, 81, 446–455. https://doi.org/10.1016/j.eururo.2021.12.039CrossRefPubMedPubMedCentral

306.

Edlind, M. P., & Hsieh, A. C. (2014). PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian Journal of Andrology, 16, 378–386. https://doi.org/10.4103/1008-682x.122876CrossRefPubMedPubMedCentral

307.

Li, Q., Wang, M., Hu, Y., Zhao, E., Li, J., Ren, L., Wang, M., Xu, Y., Liang, Q., Zhang, D., et al. (2021). MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer. Theranostics, 11, 5794–5812. https://doi.org/10.7150/thno.56604CrossRefPubMedPubMedCentral

308.

Mateo, J., Seed, G., Bertan, C., Rescigno, P., Dolling, D., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Gurel, B., Clarke, M., et al. (2020). Genomics of lethal prostate cancer at diagnosis and castration resistance. The Journal of Clinical Investigation, 130, 1743–1751. https://doi.org/10.1172/jci132031CrossRefPubMedPubMedCentral

309.

Cheng, C., Wang, J., Xu, P., Zhang, K., Xin, Z., Zhao, H., Ji, Z., Zhang, M., Wang, D., He, Y., et al. (2022). Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer. Nature Cancer, 3, 565–580. https://doi.org/10.1038/s43018-022-00380-3CrossRefPubMed

310.

Tcatchoff, L., Nespoulous, C., Pernollet, J. C., & Briand, L. (2006). A single lysyl residue defines the binding specificity of a human odorant-binding protein for aldehydes. FEBS Letters, 580, 2102–2108. https://doi.org/10.1016/j.febslet.2006.03.017CrossRefPubMed

311.

Jeong, J. H., Zhong, S., Li, F., Huang, C., Chen, X., Liu, Q., Peng, S., Park, H., Lee, Y.M., Dhillon, J., et al. (2023). Tumor-derived OBP2A promotes prostate cancer castration resistance. The Journal of Experimental Medicine, 220. https://doi.org/10.1084/jem.20211546

312.

Sharp, A., Coleman, I., Yuan, W., Sprenger, C., Dolling, D., Rodrigues, D. N., Russo, J. W., Figueiredo, I., Bertan, C., Seed, G., et al. (2019). Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. The Journal of Clinical Investigation, 129, 192–208. https://doi.org/10.1172/jci122819CrossRefPubMed

313.

Liu, Y., Yu, C., Shao, Z., Xia, X., Hu, T., Kong, W., He, X., Sun, W., Deng, Y., Liao, Y., et al. (2021). Selective degradation of AR-V7 to overcome castration resistance of prostate cancer. Cell Death & Disease, 12, 857. https://doi.org/10.1038/s41419-021-04162-0CrossRef

314.

Yuan, S., He, S. H., Li, L. Y., Xi, S., Weng, H., Zhang, J. H., Wang, D. Q., Guo, M. M., Zhang, H., Wang, S. Y., et al. (2023). A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m(6)A reader YTHDC1. Cell Death & Disease, 14, 7. https://doi.org/10.1038/s41419-022-05544-8CrossRef

315.

Zhang, N., Huang, D., Ruan, X., Ng, A. T., Tsu, J. H., Jiang, G., Huang, J., Zhan, Y., & Na, R. (2023). CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 67, 100912. https://doi.org/10.1016/j.drup.2022.100912CrossRefPubMed

316.

Sun, Y., Cronin, M. F., Mendonça, M. C. P., Guo, J., & O’Driscoll, C. M. (2023). Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 185, 106427. https://doi.org/10.1016/j.ejps.2023.106427CrossRefPubMed

317.

Tanaudommongkon, I., Tanaudommongkon, A., Prathipati, P., Nguyen, J. T., Keller, E. T., Dong, X. (2020). Curcumin nanoparticles and their cytotoxicity in docetaxel-resistant castration-resistant prostate cancer cells. Biomedicines, 8. https://doi.org/10.3390/biomedicines8080253

318.

Hoang, B., Ernsting, M. J., Tang, W. S., Bteich, J., Undzys, E., Kiyota, T., & Li, S. D. (2017). Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer. Cancer Letters, 410, 169–179. https://doi.org/10.1016/j.canlet.2017.09.029CrossRefPubMed

319.

Peng, S., Zhang, X., Huang, H., Cheng, B., Xiong, Z., Du, T., Wu, J., & Huang, H. (2022). Glutathione-sensitive nanoparticles enhance the combined therapeutic effect of checkpoint kinase 1 inhibitor and cisplatin in prostate cancer. APL Bioengineering, 6, 046106. https://doi.org/10.1063/5.0126095CrossRefPubMedPubMedCentral

320.

Yan, J., Wang, Y., Zhang, X., Liu, S., Tian, C., & Wang, H. (2016). Targeted nanomedicine for prostate cancer therapy: Docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Delivery, 23, 1757–1762. https://doi.org/10.3109/10717544.2015.1069423CrossRefPubMed

321.

Gao, Z., Huang, J., Xie, Z., Xin, P., Huang, H., Du, T., Wu, J., & Huang, H. (2022). Delivery of enzalutamide via nanoparticles for effectively inhibiting prostate cancer progression. Biomaterials Science, 10, 5187–5196. https://doi.org/10.1039/d2bm00697aCrossRefPubMed

322.

Xu, H., Sheng, G., Lu, L., Wang, C., Zhang, Y., Feng, L., Meng, L., Min, P., Zhang, L., Wang, Y., et al. (2021). GRPr-mediated photothermal and thermodynamic dual-therapy for prostate cancer with synergistic anti-apoptosis mechanism. Nanoscale, 13, 4249–4261. https://doi.org/10.1039/d0nr07196jCrossRefPubMed

323.

Wei, C. G., Zhang, R., Wei, L. Y., Pan, P., Zu, H., Liu, Y. Z., Wang, Y., & Shen, J. K. (2022). Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy. Frontiers in Bioengineering and Biotechnology, 10, 1078342. https://doi.org/10.3389/fbioe.2022.1078342CrossRefPubMedPubMedCentral

324.

Zhang, X., He, Z., Xiang, L., Li, L., Zhang, H., Lin, F., & Cao, H. (2019). Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer. Drug Design, Development and Therapy, 13, 1357–1372. https://doi.org/10.2147/dddt.S198400CrossRefPubMedPubMedCentral

325.

Liang, S., Han, L., Mu, W., Jiang, D., Hou, T., Yin, X., Pang, X., Yang, R., Liu, Y., & Zhang, N. (2018). Carboplatin-loaded SMNDs to reduce GSH-mediated platinum resistance for prostate cancer therapy. Journal of Materials Chemistry. B, 6, 7004–7014. https://doi.org/10.1039/c8tb01721bCrossRefPubMed

326.

Guo, Q., Dong, Y., Zhang, Y., Fu, H., Chen, C., Wang, L., Yang, X., Shen, M., Yu, J., Chen, M., et al. (2021). Sequential release of pooled siRNAs and paclitaxel by aptamer-functionalized shell-core nanoparticles to overcome paclitaxel resistance of prostate cancer. ACS Applied Materials & Interfaces, 13, 13990–14003. https://doi.org/10.1021/acsami.1c00852CrossRef

327.

Nagesh, P. K. B., Chowdhury, P., Hatami, E., Boya, V. K. N., Kashyap, V. K., Khan, S., Hafeez, B. B., Chauhan, S. C., Jaggi, M., Yallapu, M. M. (2018). miRNA-205 nanoformulation sensitizes prostate cancer cells to chemotherapy. Cancers, 10. https://doi.org/10.3390/cancers10090289

328.

Singh, S. K., Lillard, J. W., Jr., & Singh, R. (2018). Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. Cancer Letters, 427, 49–62. https://doi.org/10.1016/j.canlet.2018.04.017CrossRefPubMedPubMedCentral

329.

Hara, D., Tao, W., Schmidt, R. M., Yang, Y. P., Daunert, S., Dogan, N., Ford, J. C., Pollack, A., Shi, J. (2022). Boosted radiation bystander effect of PSMA-targeted gold nanoparticles in prostate cancer radiosensitization. Nanomaterials (Basel, Switzerland), 12. https://doi.org/10.3390/nano12244440

330.

Zhang, X., Liu, N., Shao, Z., Qiu, H., Yao, H., Ji, J., Wang, J., Lu, W., Chen, R. C., & Zhang, L. (2017). Folate-targeted nanoparticle delivery of androgen receptor shRNA enhances the sensitivity of hormone-independent prostate cancer to radiotherapy. Nanomedicine : Nanotechnology, Biology, and Medicine, 13, 1309–1321. https://doi.org/10.1016/j.nano.2017.01.015CrossRefPubMed

331.

Mirjolet, C., Boudon, J., Loiseau, A., Chevrier, S., Boidot, R., Oudot, A., Collin, B., Martin, E., Joy, P. A., Millot, N., et al. (2017). Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model. International Journal of Nanomedicine, 12, 6357–6364. https://doi.org/10.2147/ijn.S139167CrossRefPubMedPubMedCentral

332.

Mortensen, M. M., Høyer, S., Lynnerup, A.-S., Ørntoft, T. F., Sørensen, K. D., Borre, M., & Dyrskjøt, L. (2015). Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Scientific Reports, 5, 16018.CrossRefPubMedPubMedCentral

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Resveratrol as sensitizer in colorectal cancer plasticity

Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals

Cell plasticity modulation by flavonoids in resistant breast carcinoma targeting the nuclear factor kappa B signaling

The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies

Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review

Biographies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer